|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
61,650,000 |
Market
Cap: |
241.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.08 - $5.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Omeros is a commercial-stage biopharmaceutical company. Co. is focused on discovering, developing and commercializing small-molecule and protein therapeutics for larger-market as well as orphan indications targeting immunologic diseases. Co.'s drug candidate narsoplimab is the subject of a biologics license application pending before the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Co. has various late-stage clinical development programs in its pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A nephropathy, atypical hemolytic uremic syndrome and COVID-19.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
Total Buy Value |
$0 |
$0 |
$40,500 |
$40,500 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
10,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$64,950 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cable Thomas J. |
Director |
|
2016-12-14 |
4 |
AS |
$10.21 |
$30,642 |
D/D |
(3,000) |
43,067 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-07 |
4 |
AS |
$10.48 |
$1,069,033 |
D/D |
(102,044) |
1,884,985 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-07 |
4 |
OE |
$0.98 |
$100,003 |
D/D |
102,044 |
1,987,029 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-06 |
4 |
AS |
$10.80 |
$1,101,808 |
D/D |
(102,040) |
1,884,985 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-06 |
4 |
OE |
$0.98 |
$99,999 |
D/D |
102,040 |
1,987,025 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-05 |
4 |
AS |
$10.71 |
$1,092,644 |
D/D |
(102,040) |
1,884,985 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-05 |
4 |
OE |
$0.98 |
$99,999 |
D/D |
102,040 |
1,987,025 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-02 |
4 |
OE |
$0.98 |
$277,539 |
D/D |
283,203 |
1,884,985 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-02 |
4 |
AS |
$11.00 |
$1,122,593 |
D/D |
(102,040) |
1,703,822 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-01 |
4 |
AS |
$11.56 |
$1,232,063 |
D/D |
(106,521) |
1,703,822 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-12-01 |
4 |
OE |
$0.98 |
$104,391 |
D/D |
106,521 |
1,810,343 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-11-30 |
4 |
AS |
$12.21 |
$1,191,478 |
D/D |
(97,559) |
1,703,822 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-11-30 |
4 |
OE |
$0.98 |
$95,608 |
D/D |
97,559 |
1,801,381 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-10-12 |
4 |
OE |
$6.05 |
$18,174 |
D/D |
3,004 |
166,601 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-09-15 |
4 |
AS |
$10.91 |
$174,578 |
D/D |
(16,000) |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-09-15 |
4 |
OE |
$0.98 |
$15,680 |
D/D |
16,000 |
179,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-08-15 |
4 |
AS |
$11.56 |
$183,826 |
D/D |
(15,900) |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-08-15 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
179,497 |
|
- |
|
Cable Thomas J. |
Director |
|
2016-08-12 |
4 |
AS |
$11.52 |
$34,557 |
D/D |
(3,000) |
46,067 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-07-15 |
4 |
AS |
$11.50 |
$182,804 |
D/D |
(15,900) |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-07-15 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
179,497 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-06-15 |
4 |
AS |
$11.42 |
$181,503 |
D/D |
(15,900) |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-06-15 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
179,497 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-05-16 |
4 |
AS |
$9.94 |
$158,057 |
D/D |
(15,900) |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-05-16 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
179,497 |
|
- |
|
123 Records found
|
|
Page 4 of 5 |
|
|